Challenges in the treatment of late-identified untreated congenital adrenal hyperplasia due to CYP11B1 deficiency: Lessons from a developing country

Front Endocrinol (Lausanne). 2022 Dec 15:13:1015973. doi: 10.3389/fendo.2022.1015973. eCollection 2022.

Abstract

Background: Congenital Adrenal Hyperplasia (CAH) due to CYP11B1 is a rare autosomal recessive adrenal disorder that causes a decrease in cortisol production and accumulation of adrenal androgens and steroid precursors with mineralocorticoid activity. Clinical manifestations include cortisol deficiency, ambiguous genitalia in females (differences of sex development (DSD)), and hypertension. Medical treatment recommendations are well defined, consisting of glucocorticoid treatment to substitute glucocorticoid deficiency and consequently normalize adrenal androgen and precursors levels. Current guidelines also emphasize the need for specialized multidisciplinary DSD teams and psychosocial support. In many developing countries, care for DSD patients, especially when caused by an adrenal disease, is challenging due to the lack of infrastructure, knowledge, and medication.

Objective: The study aims to report the conflicting decision-making process of medical treatment and sex assignment in late-identified CAH patients in developing countries.

Methods: We describe the clinical and biochemical findings and the psychological assessment of five affected but untreated family members with CAH due to CYP11B1 deficiency.

Results: All patients had a 46,XX karyotype, ambiguous genitalia, low cortisol levels, and hypertension. Two identified as males, two as females, and one had undecided gender. The patients were counselled that refusing treatment will lead to infertility and the potential risk of developing Addisonian crisis and severe hypertension. However, all 46,XX CAH males refused treatment with glucocorticoids due to the expected lowering of adrenal androgens as their main source of testosterone. None of the patients developed Addisonian crisis, probably due to some residual cortisol activity and glucocorticoid activity of elevated adrenal steroid precursors.

Conclusion: Medical treatment and sex assignment in late-identified 46,XX CAH patients in Indonesia may often depend on local and cultural factors. The management of DSD conditions may have to be individualized and integrated into the psychological and social context of the affected family.

Keywords: CYP11B1 deficiency; congenital adrenal hyperplasia; developing country; differences (disorders) of sex development; guideline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Hyperplasia, Congenital* / drug therapy
  • Adrenal Hyperplasia, Congenital* / genetics
  • Androgens / therapeutic use
  • Developing Countries
  • Disorders of Sex Development* / genetics
  • Disorders of Sex Development* / therapy
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydrocortisone / therapeutic use
  • Hypertension* / etiology
  • Hypertension* / genetics
  • Male
  • Steroid 11-beta-Hydroxylase / genetics
  • Steroids / therapeutic use

Substances

  • Androgens
  • Glucocorticoids
  • Hydrocortisone
  • Steroid 11-beta-Hydroxylase
  • Steroids

Supplementary concepts

  • Congenital adrenal hyperplasia due to 11-Beta-hydroxylase deficiency

Grants and funding

This work was financially supported by Faculty of Medicine Grant, Diponegoro University, Semarang, Indonesia (PNBP FK T.A. 2016 Number 3817/UN7.3.4/PG/2016) and the WCP program-Indonesian Ministry of Research, Higher Education and Technology.